fda bpc-157 compounding category 2 list Approval Status 2026: Clinical Trials BREAKING: The FDA just reversed
BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu (injectable) BPC 157, TB 500, KPV, GHK Cu 80mg (Klow Blend) Legal Status FDA's Overreach on Compounded Peptides FDA Removes Peptides from Category 2 List, Paving Way for Regulation Jonathan Cole posted on the topic LinkedIn FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA advisory committee votes to add popular peptide BPC 157 to drug compounding list AOL
Pay in 4 interest-free payments of $7.42 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



